ArticleFrontiers in pediatrics2025
Defining post-obstructive diuresis following posterior urethral valve ablation.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Posterior urethral valves (PUV) are the most common cause of congenital lower urinary tract obstruction. Patients are at risk for post-obstructive diuresis (POD) following management of this obstruction which may prolong and/or complicate their subsequent hospital course. Despite this known physiologic effect, there is minimal data to define which patients are at highest risk for POD. Our objective was to define an initial urine output threshold for neonatal post-obstructive diuresis. Methods: A retrospective chart review was conducted on patients that were admitted to our Newborn and Infant Critical Care Unit (NICCU), in a tertiary care children's hospital, between 2004 and 2019 and underwent cystoscopic valve ablation for PUV. Outcomes of interest were length of hospital stay after posterior urethral valve ablation, serum creatinine and electrolyte values, fluid intake, and urine output at 4- and 24-h post-valve ablation. Chi-squared, Fisher's exact, and Results: Forty patients met inclusion criteria and the mean age at time of valve ablation was 11.2 days. Pre-operatively, maximum creatinine levels (ng/dl) achieved had a median value of 0.7 (IQR: 0.5-1.5). Post-operatively, the mean urine output (mL/kg/h) at 4-h was 4.2 ± 3.7, and at 24-h was 4.5 ± 2.2. Logistic regression analyses showed that those with a post-operative 24-h UOP > 3.5 ml/kg/h had more than 5 times the odds of a prolonged hospital length of stay (LOS) > 3 days (OR: 5.50; 95% CI: 1.23-24.51). Discussion: Neonates with PUV who undergo valve ablation are at risk of POD. Our findings suggest greater urine output after ablation to be a predictor of increased hospital length of stay. Utilizing a urine output (UOP) of >3.5 mL/kg/h may serve as a starting point for defining POD after posterior urethral valve ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.